STOCK TITAN

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) to provide business update and report financial results for the second quarter 2023 on August 14, 2023. Conference call to review results at 9:00 a.m. ET / 6:00 a.m. PT. Interested participants should register in advance.
Positive
  • None.
Negative
  • None.

SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023.

Second Quarter 2023 Conference Call Details
Date: Monday, August 14, 2023
Time: 9:00 a.m. ET / 6:00 a.m. PT
Participant Registration: https://edge.media-server.com/mmc/p/2qtrmqz3

Interested participants should register for the conference call in advance of the call’s start time.

Following the call, a recording will be made available on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com

FORWARD LOOKING STATEMENTS
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the expected timing of releasing data, any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of (Z)-endoxifen, anticipated progress on Atossa’s (Z)-endoxifen development program, anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density or in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for (Z)-endoxifen, whether Atossa can complete acquisitions, anticipated working capital needs and expectations around the sufficiency of our cash reserves, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


FAQ

What is the company name and ticker symbol mentioned in the press release?

Atossa Therapeutics, Inc. (Nasdaq: ATOS)

When will the company provide a business update and report financial results for the second quarter 2023?

On Monday, August 14, 2023.

What time will the conference call to review the results take place?

At 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023.

Where can interested participants register for the conference call?

They can register at https://edge.media-server.com/mmc/p/2qtrmqz3.

Where will a recording of the call be made available?

On the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com

Atossa Therapeutics, Inc.

NASDAQ:ATOS

ATOS Rankings

ATOS Latest News

ATOS Stock Data

165.43M
125.73M
0.06%
28.21%
10.15%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SEATTLE